β2-adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma.

ABSTRACT:

Background

Vascular endothelial growth factor (VEGF) was initially known as vascular permeability factor and identified as a driver of tumour angiogenesis. Recently, its role in supporting an immunosuppressive tumour microenvironment was demonstrated, and anti-VEGF treatment combined with immune checkpoint blockade is currently investigated. Further, beta-adrenergic signalling as a modifier of cancer hallmarks like immune response, angiogenesis and metastasis gained increased attention during past years.

Methods

Focusing on the aspect of immunosuppression in upregulated beta-adrenergic signalling, we investigated predictive markers in patients with metastatic melanoma who received bevacizumab monotherapy, a specific VEGF-A binding antibody. We explored the expression of beta

SUBMITTER: Schuster C 

PROVIDER: S-EPMC10524038 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature